Bank of New York Mellon Corp Takes Position in Bioventus Inc. $BVS

Bank of New York Mellon Corp purchased a new position in shares of Bioventus Inc. (NASDAQ:BVS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 152,316 shares of the company's stock, valued at approximately $1,438,000. Bank of New York Mellon Corp owned 0.18% of Bioventus at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in shares of Bioventus by 40.3% during the first quarter. Bank of America Corp DE now owns 86,057 shares of the company's stock valued at $786,000 after buying an additional 24,723 shares during the last quarter. Engine Capital Management LP bought a new stake in shares of Bioventus during the first quarter worth $2,876,000. Quantinno Capital Management LP lifted its position in shares of Bioventus by 119.6% during the first quarter. Quantinno Capital Management LP now owns 72,023 shares of the company's stock worth $658,000 after purchasing an additional 39,222 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of Bioventus by 12.9% during the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company's stock valued at $2,789,000 after purchasing an additional 35,008 shares during the period. Finally, Sei Investments Co. grew its holdings in shares of Bioventus by 160.7% in the first quarter. Sei Investments Co. now owns 289,648 shares of the company's stock worth $2,644,000 after purchasing an additional 178,539 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Price Performance

Shares of BVS opened at $13.63 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.69. The company has a 50 day moving average price of $13.14 and a 200-day moving average price of $10.66. Bioventus Inc. has a fifty-two week low of $6.26 and a fifty-two week high of $15.89. The stock has a market capitalization of $1.15 billion, a PE ratio of 17.70, a PEG ratio of 1.76 and a beta of 0.65.

Bioventus (NASDAQ:BVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. The company had revenue of $153.21 million for the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities analysts predict that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BVS. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Canaccord Genuity Group upped their target price on shares of Bioventus from $15.00 to $19.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Weiss Ratings raised shares of Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, August 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 target price on shares of Bioventus in a research report on Monday, August 17th. Finally, Craig Hallum reaffirmed a "buy" rating and set a $18.00 price target on shares of Bioventus in a research note on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $16.80.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NASDAQ:BVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.